BCM
CRVS icon

BML Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

BML Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-118,766
Closed -$475K – 20
2025
Q2 		$475K Buy
+118,766
New +$432K 0.36% 20

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BML Capital Management's CRVS Position: Q3 2025 in Review

BML Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2025, closing a stake of 118,766 shares — an estimated $475K sold.

BML Capital Management first reported a position in CRVS in Q2 2025 and held it in 1 quarter. The position peaked at $475K in Q2 2025. 102 funds tracked by Wall St. Rank hold CRVS as of Q3 2025.

  • BML Capital Management reported no remaining Corvus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • BML Capital Management sold 118,766 Corvus Pharmaceuticals shares in Q3 2025, an estimated $475K.
  • BML Capital Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • BML Capital Management's Corvus Pharmaceuticals position peaked at $475K in Q2 2025.
  • 102 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2025.

Based on BML Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.